Increased carcass fat levels are re...

Increased carcass fat levels are related to a large number of comorbid conditions, like as cardiac disease, diabetes, and cancer. generally available drugs are useful further do not always bring about the desired goal. Weigle reviewed the past, instant and future of pharmacologic treatments for obesity.

Past treatments included thyroid hormone therapy, yet patients lost lean body mass, and calcium and nitrogen excretion increased. Patients frequently developed symptoms of hyperthyroidism as it was as tachycardia and arrhythmias, and weight was rapidly regained after therapy was stopped. Amphetamines also were used as weight los agents, if it were not that their use often resulted in hypertension, addiction, and adverse myocardial results Fenfluramine, which increased serotonin evens was used alone or in combination with the sympathomimetic agent phentermine. Fenfluramine was an effective long-term treatment for obesity, on the other hand its use resulted in cases of primary pulmonary hypertension. Fenfluramine later was associated with valvular heart disease. Phenylpropanolamine, another sympathomimetic medicine was removed from the market lately because of resultant hemorrhagic thumps Ephedra has been associated with hypertension, tachycardia, visitation seizures, and death.

now passing pharmacologic treatments for obesity are listed in the accompanying table. The brace major mechanisms of action are an increase in norepinephrine and serotonin plains in the central nervous plan which promotes anorexia, and decreased fat absorption from the embowel Sibutramine blocks norepinephrine and serotonin reuptake and encourages weight loss with long-term therapy, increasing the likelihood that patients who throw away weight will not regain it. Side consequences include elevated blood pressure and heart rate, headache, insomnia, craving drink mouth, and constipation. Orlistat inhibits gastrointestinal lipases, resulting in decreased fat absorption. Because the unsalable article is not systemically absorbed, side forces are confined to the gastrointestinal tract; set free stools, increased defection, fecal emergency and oily stools have been reported in patients taking orlistat. Patients taking sibutramine or orlistat generally fail to win less than 10 percent of their corpse weight, and many patients regain weight after they stop treatment.

The National Institutes of Health attract favor tos diet modification, exercise, and behavior therapy for initial weight los If these arrangements do not result in weight los of 10 percent of corpse weight within six months, pharmacotherapy can be started in patients with a carcass mass index (BMI) of at least 30 kg by [m.sup.2], or in patients with a BMI of at least 27 kg by [m.sup.2] who have other morbidity-related risk factors so as hypertension, dyslipidemia, diabetes, coronary artery disease, or be motionless apnea. If weight loss does not happen within the first four weeks of pharmacotherapy, the medication or its dosage should be reevaluated.

The general pharmacologic therapies for obesity are inadequate, and weight reduction generally is limited to 10 percent of visible form [i]or[/i] frame weight. Even with weight los physiologic signals that increase appetite and decrease animal spirits expenditure make maintenance of weight los difficult. Newer antiobesity physics may modulate these long-acting hormonal signals that affect mechanical value balance sites in the central nervous body Leptin, insulin, and ghrelin regulation may allow more favorable efficacy balance by affecting hunger.

The author judges that current medications to enhance weight los are marginally effective, especially for long-term therapy. Improved knowledge about the regulation of visible form [i]or[/i] frame fat and total body manliness stores will result in better medications.

Weigle D Pharmacological therapy of obesity: past, near and future. J Clin Endocrinol Metab June 2003;88: 2462-9

COPYRIGHT 2004 American Academy of Family Physicians

COPYRIGHT 2004 Gale Group